Clinical trials
Observational Reinfection trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
18 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 2 |
| 2005 | 2 |
| 2007 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2018 | 2 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 9 |
| Completed | 5 |
| Active, not recruiting | 2 |
| Recruiting | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Taiwan University Hospital | 3 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 2 |
| First Affiliated Hospital of Fujian Medical University | 1 |
| Goztepe Training and Research Hospital | 1 |
| Groupe Hospitalier Diaconesses Croix Saint-Simon | 1 |
| Jiming Zhang | 1 |
| Kirby Institute | 1 |
| Magdalena Salcedo | 1 |
| O & O Alpan LLC | 1 |
| Peking University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Reinfection | 18 |
| COVID-19 | 4 |
| Hepatitis C | 2 |
| Primary Immunodeficiency Diseases | 2 |
| Acquired Immunodeficiency Syndrome | 1 |
| Agammaglobulinemia | 1 |
| Autoimmune Diseases | 1 |
| Bronchiolitis Obliterans Syndrome | 1 |
| Coinfection | 1 |
| Genetic Diseases, Inborn | 1 |
Trials
Showing 26 to 18 of 18. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.